"Here, we performed a randomized controlled clinical trial with convalescent/vaccinated plasma in high-risk patients, including patients with cancer with severe COVID-19, and analyzed the association between plasma therapy and the response of neutralizing antibody titers in plasma recipients."
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial - Nature Cancer
Müller-Tidow and colleagues perform a randomized clinical trial and show that administration of convalescent plasma improves COVID-19 outcome in patients with cancer who are unable to generate an adequate immune response.